hypophosphatemia

Hyperparathyroidism Secondary to Burosumab Treatment

Nguyen MK, Bandaru D, Nguyen MK. Hyperparathyroidism Secondary to Burosumab Treatment. Cureus. 2025 Aug 7;17(8):e89569. doi: 10.7759/cureus.89569. PMID: 40922882; PMCID: PMC12413978.

By afschroeder • September 9, 2025

Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement

Rosano G, Ezekowitz J, Nemeth E, Ponikowski P, Rauner M, Seid M, Spahn DR, Stein J, Wish J, Mentz RJ. Evaluating the Risk of Hypophosphatemia[...]

By afschroeder • July 29, 2025